| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
146,000,000 |
| Market
Cap: |
16.22(B) |
| Last
Volume: |
1,035,875 |
Avg
Vol: |
1,333,523 |
| 52
Week Range: |
$92.79 - $212.65 |
|
| Level
I Sector: |
Information Technology |
| Level
II Sector: |
Electronics |
| Level
III Sector: |
Scientific & Technical Instruments |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : 11.4 |
| Insider 6 Months : 11.4 |
| Insider 3/6 Months : 23.2 |
|
| Guru Rank Number : 691 |
| Guru Rank Value : 2.3 |
| Guru Occurances : 3 |
|
|
|
|
|
| |
|
Company Profile Illumina is engaged in sequencing- and array-based solutions for genetic and genomic analysis. Co. provides whole-genome sequencing, genotyping, noninvasive prenatal testing (NIPT), and product support services. Using Co.'s services, customers can perform whole-genome sequencing projects and microarray projects (including large-scale genotyping studies and whole-genome association studies). Co. provides NIPT services through its partner laboratories that direct samples to Co. on a test send-out basis in its Clinical Laboratory Improvements Amendments-certified, College of Pathologists-accredited laboratory. Co. also provides support services to customers who have purchased its products.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
7,330 |
7,330 |
7,330 |
7,330 |
| Total Buy Value |
$991,672 |
$991,672 |
$991,672 |
$991,672 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
1 |
1 |
1 |
| Total Shares Sold |
0 |
0 |
6,815 |
22,740 |
| Total Sell Value |
$0 |
$0 |
$1,357,080 |
$4,648,975 |
| Total People Sold |
0 |
0 |
2 |
3 |
| Total Sell Transactions |
0 |
0 |
5 |
17 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Dadswell Charles |
SVP & General Counsel |
• • – |
2020-02-11 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,624 |
16,943 |
|
- |
|
| Dadswell Charles |
SVP & General Counsel |
• • – |
2020-02-11 |
4 |
A |
$0.00 |
$0 |
D/D |
3,812 |
9,319 |
|
- |
|
| Mcginnis Karen K |
VP, Chief Accounting Officer |
• • – |
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
999 |
3,240 |
|
- |
|
| Goswami Joydeep |
SVP Corp Business Development |
• • – |
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
1,665 |
2,992 |
|
- |
|
| Hoyt Aimee L |
SVP, Chief People Officer |
• • – |
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
1,873 |
4,106 |
|
- |
|
| Desouza Francis A |
President and CEO |
• • – |
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
8,324 |
66,041 |
|
- |
|
| Ostadan Omead |
SVP Mktg, Prod & Strat Plan |
• • – |
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
2,498 |
10,411 |
|
- |
|
| Febbo Phillip G. |
SVP Chief Medical Officer |
• • – |
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
1,249 |
2,755 |
|
- |
|
| Dadswell Charles |
SVP & General Counsel |
• • – |
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
1,873 |
5,507 |
|
- |
|
| Tousi Susan H |
SVP Product Development |
• • – |
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
2,081 |
40,620 |
|
- |
|
| Ronaghi Mostafa |
SVP & CTO |
• • – |
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
1,665 |
77,140 |
|
- |
|
| Ragusa Robert P |
SVP, Global Quality & Ops |
• • – |
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
2,081 |
10,022 |
|
- |
|
| Van Oene Mark |
SVP Chief Commercial Officer |
• • – |
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
2,081 |
12,704 |
|
- |
|
| Samad Samer Abdul |
SVP and CFO |
• • – |
2020-02-05 |
4 |
A |
$0.00 |
$0 |
D/D |
1,457 |
4,468 |
|
- |
|
| Van Oene Mark |
SVP Chief Commercial Officer |
• • – |
2020-02-05 |
4 |
AS |
$300.24 |
$187,650 |
D/D |
(625) |
10,623 |
|
20% |
|
| Gottlieb Scott |
Director |
• • – |
2020-02-04 |
4 |
A |
$0.00 |
$0 |
D/D |
395 |
395 |
|
- |
|
| Ragusa Robert P |
SVP, Global Quality & Ops |
• • – |
2020-02-03 |
4 |
AS |
$293.10 |
$367,254 |
D/D |
(1,253) |
7,888 |
|
18% |
|
| Samad Samer Abdul |
SVP and CFO |
• • – |
2020-02-03 |
4 |
AS |
$293.10 |
$69,758 |
D/D |
(238) |
3,011 |
|
18% |
|
| Hampton Malcolm Garret |
SVP Clinical Genomics Group |
• • – |
2020-01-09 |
4 |
D |
$334.60 |
$109,080 |
D/D |
(326) |
6,598 |
|
- |
|
| Hoyt Aimee L |
SVP, Chief People Officer |
• • – |
2020-01-08 |
4 |
D |
$332.16 |
$51,817 |
D/D |
(156) |
2,170 |
|
- |
|
| Tousi Susan H |
SVP Product Development |
• • – |
2020-01-06 |
4 |
AS |
$325.00 |
$65,000 |
D/D |
(200) |
38,465 |
|
-1% |
|
| Samad Samer Abdul |
SVP and CFO |
• • – |
2020-01-06 |
4 |
D |
$325.53 |
$69,012 |
D/D |
(212) |
3,249 |
|
- |
|
| Van Oene Mark |
SVP Chief Commercial Officer |
• • – |
2020-01-02 |
4 |
AS |
$330.38 |
$206,868 |
D/D |
(625) |
11,178 |
|
-2% |
|
| Flatley Jay T |
Director |
• • – |
2020-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
446 |
258,970 |
|
- |
|
| Flatley Jay T |
Director |
• • – |
2019-12-11 |
4 |
D |
$320.57 |
$966,519 |
D/D |
(3,015) |
258,524 |
|
- |
|
3466 Records found
|
|
Page 18 of 139 |
|
|
3.39 (2.96%) 
